Nordicus Partners Corporation Corporate Update

Nordicus Partners announced positive preclinical results for its subsidiary Orocidin's QR-01 treatment for aggressive periodontitis, demonstrating efficacy in both beagle and rat studies with reduced bone loss confirmed by micro-CT imaging. Phase IIa clinical trials are planned for H1 2027 at the University of Copenhagen. Bio-Convert received a toxicity waiver for QR-02 (oral leukoplakia treatment) with GMP manufacturing on track for December 2026, while NoviThera established biological proof of concept for QR-04 psoriasis treatment. The company's Nasdaq uplisting application remains under active review.